報價延遲最少15分鐘:2024/12/23 22:17 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3024 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-17.53/-2.13
|
|
企業價值
2.47M
|
| 資產負債 |
|
每股賬面淨值
0.32
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:17 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD). |